Drugs / Y-90 Humanized Anti-Tac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00001575 | Apr 1997 → Nov 2013 | Hodgkins lymphoma, non-Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-90 Humanized Anti-Tac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001575 ↗ |
| Known as | 90 Y-HAT | “This study will examine the use of a radioactive monoclonal antibody called yttrium 90-labeled humanized anti-Tac (90 Y-HAT) for treating certain cancers.” NCT00001575 ↗ |
| Modality | Monoclonal antibody | “radioactive monoclonal antibody” NCT00001575 ↗ |
| Route | Intravenous | “90 Y-HAT is given through a vein (intravenous (IV)) over a 2-hour period.” NCT00001575 ↗ |